Crescita Therpeutc (TSE:CTX) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Crescita Therapeutics reported a revenue increase of 18.5% in Q3 2024, driven by growth in its Skincare segment and higher licensing revenue. The company is also enhancing its manufacturing capabilities with new equipment and a long-term agreement with a major client, aiming to boost profitability and secure a new partner for Pliaglis in the U.S.
For further insights into TSE:CTX stock, check out TipRanks’ Stock Analysis page.